drugset / Trial / NCT02490488
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.
Timeline
- Start
- 2014-04
- Primary completion
- 2020-12
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masitinib | Small molecule | 6 mg/kg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |